MEDIFAST INC (MED): Price and Financial Metrics


MEDIFAST INC (MED): $207.26

-3.12 (-1.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MED POWR Grades


  • MED scores best on the Quality dimension, with a Quality rank ahead of 97.63% of US stocks.
  • The strongest trend for MED is in Momentum, which has been heading down over the past 52 weeks.
  • MED ranks lowest in Momentum; there it ranks in the 10th percentile.

MED Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MED is 7.2 -- better than 95.66% of US stocks.
  • For MED, its debt to operating expenses ratio is greater than that reported by only 7.53% of US equities we're observing.
  • As for revenue growth, note that MED's revenue has grown 68.12% over the past 12 months; that beats the revenue growth of 89.56% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Medifast Inc, a group of peers worth examining would be SPWH, SFM, ABG, LFVN, and MAN.
  • MED's SEC filings can be seen here. And to visit Medifast Inc's official web site, go to medifastinc.com.

MED Valuation Summary

  • MED's price/earnings ratio is 18.1; this is 6.7% lower than that of the median Consumer Cyclical stock.
  • Over the past 243 months, MED's price/earnings ratio has gone up 15.6.
  • MED's price/sales ratio has moved up 1.6 over the prior 243 months.

Below are key valuation metrics over time for MED.

Stock Date P/S P/B P/E EV/EBIT
MED 2021-08-27 2.1 14.0 18.1 12.9
MED 2021-08-26 2.1 13.4 17.3 12.4
MED 2021-08-25 2.0 13.4 17.3 12.4
MED 2021-08-24 2.1 13.5 17.4 12.5
MED 2021-08-23 2.1 13.7 17.7 12.7
MED 2021-08-20 2.1 13.4 17.4 12.4

MED Growth Metrics

  • The 3 year net cashflow from operations growth rate now stands at 179.99%.
  • The year over year cash and equivalents growth rate now stands at 127.23%.
  • Its 5 year cash and equivalents growth rate is now at 115.69%.
Over the past 33 months, MED's revenue has gone up $912,162,000.

The table below shows MED's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 1,413.165 121.833 158.002
2021-06-30 1,271.24 147.147 150.473
2021-03-31 1,097.05 183.787 125.445
2020-12-31 934.842 145.196 102.859
2020-09-30 840.562 144.519 94.746
2020-06-30 759.153 121.302 76.195

MED's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MED has a Quality Grade of A, ranking ahead of 99.43% of graded US stocks.
  • MED's asset turnover comes in at 4.143 -- ranking 1st of 59 Food Products stocks.
  • TWNK, TOFB, and KHC are the stocks whose asset turnover ratios are most correlated with MED.

The table below shows MED's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 4.143 0.744 19.148
2021-03-31 4.006 0.739 72.885
2020-12-31 3.851 0.746 8.172
2020-09-30 3.779 0.746 4.378
2020-06-30 3.670 0.745 2.384
2020-03-31 3.596 0.753 1.821

MED Price Target

For more insight on analysts targets of MED, see our MED price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $363.33 Average Broker Recommendation 1.33 (Strong Buy)

MED Stock Price Chart Interactive Chart >

Price chart for MED

MED Price/Volume Stats

Current price $207.26 52-week high $336.99
Prev. close $210.38 52-week low $183.46
Day low $206.00 Volume 10,141
Day high $209.41 Avg. volume 120,541
50-day MA $206.74 Dividend yield 2.7%
200-day MA $245.51 Market Cap 2.41B

MEDIFAST INC (MED) Company Bio


Medifast Inc. is a manufacturer and provider of clinically weight-loss and weight-maintenance products and programs. The company was founded in 1980 and is based in Owings Mills, Maryland.


MED Latest News Stream


Event/Time News Detail
Loading, please wait...

MED Latest Social Stream


Loading social stream, please wait...

View Full MED Social Stream

Latest MED News From Around the Web

Below are the latest news stories about Medifast Inc that investors may wish to consider to help them evaluate MED as an investment opportunity.

Should Value Investors Pick Medifast (MED) Stock Now?

Is Medifast (MED) a great pick from the value investor's perspective right now? Read on to know more.

Yahoo | November 16, 2021

Notable Medifast Insider Makes $970K Buy

Jeffrey Brown, Insider at Medifast (NYSE:MED), made a large insider buy on November 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Brown purchased 4,200 shares of Medifast at at prices ranging from $218.49 to $235.28. The total transaction amounted to $973,911. Brown now owns a total of 34,957 of Medifast worth, 8,002,188. Medifast shares are trading up 2.77% at $228.92 at the time of this writing on Thursda

Yahoo | November 11, 2021

4 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. CommScope The Trade: Com

Yahoo | November 11, 2021

Medifast CEO: 'We changed our business model to be focused on coaches'

Medifast CEO Dan Chard discusses how his company has outpaced 2021 and Q3 estimates, as it has modified its healthy living service model to focus more on direct-to-consumer.

Yahoo | November 9, 2021

Medifast (NYSE:MED) Issues Earnings Results, Beats Estimates By $0.64 EPS

Medifast (NYSE:MED) issued its quarterly earnings data on Thursday. The specialty retailer reported $3.56 earnings per share for the quarter, beating the Zacks consensus estimate of $2.92 by $0.64, MarketWatch Earnings reports. The company had revenue of $413.40 million for the quarter, compared to the consensus estimate of $402.80 million. Medifast had a net margin []

Transcript Daily | November 7, 2021

Read More 'MED' Stories Here

MED Price Returns

1-mo 5.60%
3-mo -9.16%
6-mo -33.77%
1-year 3.98%
3-year 53.00%
5-year 512.78%
YTD 7.50%
2020 86.18%
2019 -9.73%
2018 82.11%
2017 72.33%
2016 41.31%

MED Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full MED Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8818 seconds.